• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

Dr. Matthew O'Connor - Underdog Pharmaceuticals and SENS

sens pharmaceuticals podcast underdog pharmaceuticals cyclodextrins

  • Please log in to reply
2 replies to this topic

#1 onz

  • Guest
  • 119 posts
  • 809
  • Location:Japan

Posted 12 April 2020 - 09:29 AM


Coming up next week is an interview with Dr. O'Connor, co-founder of Underdog Pharmaceuticals. He also previously worked with SENS as the Vice President of Research.

 

Underdog Pharmaceuticals is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.

 

We last interviewed Dr. O'Connor about his role with SENS, so it will be interesting to hear about this new project and what he's focusing on for the future. If you have any questions for the interview please let us know in the comments below :)

Attached Files



#2 Mind

  • Life Member, Director, Moderator, Treasurer
  • 19,348 posts
  • 2,000
  • Location:Wausau, WI

Posted 23 April 2020 - 05:53 PM

This podcast is now recorded and should be live on the podcast page within a couple of days. 



#3 Mind

  • Life Member, Director, Moderator, Treasurer
  • 19,348 posts
  • 2,000
  • Location:Wausau, WI

Posted 07 May 2021 - 08:10 PM

Check out the latest update on the progress at Underdog Pharmaceuticals with Dr. Matthew OConnor.

 

Now live on the podcast page.

 

2021 Interview with Dr. Matthew OConnor.







Also tagged with one or more of these keywords: sens, pharmaceuticals, podcast, underdog pharmaceuticals, cyclodextrins

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users